Total Payments
$603,205
2024 Payments
$157,089
Companies
35
Transactions
435
Medicare Patients
942
Medicare Billing
$224,594
Payment Breakdown by Category
Consulting$356,099 (59.0%)
Other$178,900 (29.7%)
Travel$50,171 (8.3%)
Food & Beverage$10,154 (1.7%)
Research$6,381 (1.1%)
Education$1,500 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $356,099 | 138 | 59.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $165,644 | 46 | 27.5% |
| Travel and Lodging | $50,171 | 117 | 8.3% |
| Honoraria | $13,150 | 7 | 2.2% |
| Food and Beverage | $10,154 | 122 | 1.7% |
| Unspecified | $6,381 | 3 | 1.1% |
| Education | $1,500 | 1 | 0.2% |
| Grant | $106.00 | 1 | 0.0% |
Payments by Type
General
$596,824
432 transactions
Research
$6,381
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $193,193 | 140 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $177,481 | 90 | $0 (2024) |
| Janssen Biotech, Inc. | $42,107 | 34 | $0 (2024) |
| GENZYME CORPORATION | $23,153 | 16 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $22,095 | 16 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $15,116 | 9 | $0 (2024) |
| PFIZER INC. | $12,724 | 9 | $0 (2024) |
| Mirati Therapeutics, Inc. | $12,059 | 11 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $11,324 | 17 | $0 (2023) |
| Janssen Global Services, LLC | $10,140 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $157,089 | 119 | JAZZ PHARMACEUTICALS INC. ($63,317) |
| 2023 | $191,970 | 159 | JAZZ PHARMACEUTICALS INC. ($81,201) |
| 2022 | $123,894 | 83 | AstraZeneca Pharmaceuticals LP ($52,681) |
| 2021 | $58,160 | 26 | AstraZeneca Pharmaceuticals LP ($31,595) |
| 2020 | $49,337 | 24 | AstraZeneca Pharmaceuticals LP ($23,655) |
| 2019 | $14,075 | 12 | AstraZeneca Pharmaceuticals LP ($9,495) |
| 2018 | $7,575 | 5 | Eli Lilly and Company ($5,903) |
| 2017 | $1,105 | 7 | Merck Sharp & Dohme Corporation ($719.40) |
All Payment Transactions
435 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $33.16 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $47.38 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $204.18 | General |
| 12/12/2024 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,450.00 | General |
| 12/09/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $135.78 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $131.78 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $43.78 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $219.46 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $285.32 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $174.30 | General |
| 11/22/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $281.84 | General |
| 11/14/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: NONE | ||||||
| 11/04/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $46.47 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 09/30/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,340.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/21/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $1,085.87 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/20/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| 09/20/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/08/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $118.38 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $100.21 | General |
| 09/08/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $58.53 | General |
| 09/07/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $803.56 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1A-1B TRIAL INVESTIGATING THE CSF-1R INHIBITOR LY3022855 IN COMBINATION WITH DURVALUMAB -MEDI4736- OR TREMELIMUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | Eli Lilly and Company | $5,903 | 1 |
| A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | Regeneron Pharmaceuticals, Inc. | $477.67 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 224 | 504 | $315,535 | $49,287 |
| 2022 | 7 | 204 | 475 | $295,904 | $45,192 |
| 2021 | 5 | 209 | 730 | $425,229 | $68,084 |
| 2020 | 8 | 305 | 757 | $439,515 | $62,031 |
Total Patients
942
Total Services
2,466
Medicare Billing
$224,594
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 113 | 361 | $198,550 | $30,306 | 15.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 49 | 78 | $58,110 | $9,918 | 17.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 50 | 50 | $53,250 | $8,160 | 15.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 15 | $5,625 | $902.40 | 16.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 95 | 342 | $188,100 | $28,557 | 15.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 45 | $33,525 | $6,063 | 18.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 28 | 28 | $29,820 | $4,808 | 16.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 15 | $21,240 | $2,730 | 12.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 14 | $10,010 | $1,227 | 12.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 20 | $7,500 | $1,086 | 14.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 11 | $5,709 | $722.26 | 12.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 114 | 628 | $345,400 | $55,395 | 16.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 46 | 46 | $48,209 | $7,760 | 16.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 14 | 14 | $10,430 | $1,908 | 18.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 16 | $11,440 | $1,517 | 13.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 24 | 26 | $9,750 | $1,505 | 15.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 88 | 497 | $273,350 | $35,806 | 13.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 47 | 47 | $50,055 | $7,462 | 14.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 34 | 34 | $35,190 | $6,345 | 18.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 39 | 67 | $24,455 | $4,213 | 17.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 40 | 53 | $19,875 | $2,456 | 12.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 22 | 22 | $16,710 | $2,309 | 13.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 18 | 18 | $9,810 | $1,796 | 18.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 17 | 19 | $10,070 | $1,645 | 16.3% |
About Dr. Joshua Sabari, M.D
Dr. Joshua Sabari, M.D is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2011. The National Provider Identifier (NPI) number assigned to this provider is 1356638894.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joshua Sabari, M.D has received a total of $603,205 in payments from pharmaceutical and medical device companies, with $157,089 received in 2024. These payments were reported across 435 transactions from 35 companies. The most common payment nature is "Consulting Fee" ($356,099).
As a Medicare-enrolled provider, Sabari has provided services to 942 Medicare beneficiaries, totaling 2,466 services with total Medicare billing of $224,594. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location New York, NY
- Active Since 07/05/2011
- Last Updated 06/13/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356638894
Products in Payments
- ZEPZELCA (Drug) $193,118
- IMFINZI (Biological) $105,296
- TAGRISSO (Drug) $38,643
- RYBREVANT (Drug) $37,747
- IMFINZI (Drug) $20,505
- KRAZATI (Drug) $12,059
- LIBTAYO (Biological) $11,182
- GILOTRIF (Drug) $8,006
- XALKORI (Drug) $6,602
- TABRECTA (Drug) $6,266
- Alecensa (Biological) $5,632
- Trodelvy (Drug) $4,410
- COSELA (Drug) $3,019
- ALUNBRIG (Drug) $2,400
- EXKIVITY (Drug) $2,363
- Tepotinib $2,070
- ONIVYDE (Drug) $1,500
- BRUKINSA (Drug) $1,050
- LORBRENA (Drug) $1,000
- GENEXPERT (Device) $950.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Ajai Chari, M.d, M.D
Hematology & Oncology — Payments: $536,082
Hematology & Oncology $536,082